Zai Lab

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

• Webinar: The China Advantage: Rewriting Clinical Development (SEP 24, 10am EST | Register)
• Webinar: Global Clinical Trial Disclosure: Are You Casting a Line or a Net? (SEP 29, 11am EST | Register)

DEALS & FINANCING (incl. M&As, Licensing, Financing)

• M&A: Curium to Acquire Lantheus for up to $8B
• M&A: Integer Holdings to be Taken Private Through KKR Buy-Out for $5.7B
• M&A: Jazz to Acquire Actio Biosciences for up to $1.3B
• Licensing: Genentech Enters $2.3B Licensing Agreement with Hanmi for Obesity Candidate ($190M upfront)
• Licensing: Alphamab Oncology Licenses TROP2/HER3 Bispecific ADC to Pathos AI in Potential $2.2B Deal ($125M upfront)
• Licensing: SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim' from Biohaven totalling $795M ($400M upfront)
• Financing: Braveheart Bio Nets $409M in Nasdaq IPO; Overallotment Fully Exercised
• Financing: Vaderis Raises $152M in Series B Financing
• Financing: Expedition Therapeutics Raises $115M in Oversubscribed Series B Round

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

• Positive: Agenus | BOT+BAL Updated Phase 2 NEST publication demonstrates zero recurrences and deep pathologic responses in resectable colon cancer
• Positive: AstraZeneca | Tagrisso + Orpathys delivers dual PFS and OS win in MET-driven post-Tagrisso NSCLC
• Positive: Moderna | mRNA cancer therapy delivers first Phase III win, validating the intismeran platform and extending Merck's melanoma franchise
• Positive: Alumis | Alumis envudeucitinib's long-term data supports a credible third TYK2 alternative, but not as category leader
• Positive: Agenus | Off-the-Shelf iNKT Cell Therapy Shows Early Promise Where No Approved Treatment Exists
• Negative: Tenax | TNX-103 misses Phase III LEVEL primary endpoint in PH-HFpEF but efficacy and biomarker signals support development in enriched population
• Negative: Bausch + Lomb | Phase II miss at day 29 narrows lifitegrast + perfluorohexyloctane dual-action dry eye claim to speed of onset

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

• Report: The Use of AI in Pharmaceutical Commercialization: Insights from the Field (Link)
• Report: Radiopharmaceuticals Landscape Snapshot (Link)
• Report: Dealmaking Quarterly Statistics, Q2 2026
• Report: Financing Quarterly Statistics, Q2 2026
• Report: What Good LBE Forecasting Actually Looks Like
• Report: Epi & Market Forecast - Breast Cancer HER2+ | Depression | Systemic Lupus Erythematosus
• Report: KOL Interview - HER2-Positive Breast Cancer